MCID: NNT008
MIFTS: 41

Neonatal Abstinence Syndrome

Categories: Mental diseases

Aliases & Classifications for Neonatal Abstinence Syndrome

MalaCards integrated aliases for Neonatal Abstinence Syndrome:

Name: Neonatal Abstinence Syndrome 12 44 15 17 70
Drug Withdrawal Syndrome in Newborn 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9828
ICD9CM 34 779.5
MeSH 44 D009357
SNOMED-CT 67 414819007
ICD10 32 P96.1
UMLS 70 C0027609 C1332133

Summaries for Neonatal Abstinence Syndrome

Disease Ontology : 12 A withdrawal disorder that is characterized by a group of problems that occur in a newborn who was exposed to addictive illegal or prescription drugs while in the mother's womb or postnatally following the discontinuance of drug treatment.

MalaCards based summary : Neonatal Abstinence Syndrome, also known as drug withdrawal syndrome in newborn, is related to withdrawal disorder and chronic pain. An important gene associated with Neonatal Abstinence Syndrome is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Cytochrome P450 - arranged by substrate type. The drugs Methadone and Guaifenesin have been mentioned in the context of this disorder. Affiliated tissues include fetal brain, placenta and heart.

Related Diseases for Neonatal Abstinence Syndrome

Diseases related to Neonatal Abstinence Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 96)
# Related Disease Score Top Affiliating Genes
1 withdrawal disorder 30.8 PNOC PDYN OPRM1 OPRK1
2 chronic pain 30.4 PNOC OPRM1 COMT
3 substance abuse 30.3 PDYN OPRM1 CYP2D6 COMT
4 opiate dependence 30.3 PDYN OPRM1 OPRL1 OPRK1 OPRD1
5 opioid addiction 30.1 PNOC OPRM1 OPRK1 OPRD1 CYP2B6 COMT
6 opioid abuse 29.5 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
7 drug dependence 29.5 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
8 diarrhea 28.8 PPIG CYP3A4 CYP2D6
9 pain agnosia 28.5 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
10 migraine with or without aura 1 28.2 PPIG PNOC PDYN OPRM1 CYP3A4 CYP2D6
11 disease of mental health 27.2 UGT2B7 PPIG PNOC PDYN OPRM1 OPRL1
12 tremor 10.5
13 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.3
14 separation anxiety disorder 10.2 OPRM1 COMT
15 sickle cell disease 10.2
16 impulse control disorder 10.2 OPRM1 COMT
17 pathological gambling 10.2 OPRM1 COMT
18 paine syndrome 10.1 PNOC OPRM1 COMT
19 fibromyalgia 10.1 PNOC OPRM1 COMT
20 tardive dyskinesia 10.1 CYP2D6 COMT
21 cleft palate, isolated 10.1
22 strabismus 10.1
23 torticollis 10.1
24 syphilis 10.1
25 cleft lip 10.1
26 mechanical strabismus 10.1
27 pathologic nystagmus 10.1
28 hypoglycemia 10.1
29 isolated cleft lip 10.1
30 cleft lip/palate 10.1
31 pik3ca-related overgrowth syndrome 10.1
32 acute frontal sinusitis 10.0 PPIG CYP2B6
33 amnestic disorder 10.0 PDYN OPRM1
34 hemorrhagic cystitis 10.0 PPIG CYP2B6
35 mixed epithelial stromal tumour 10.0 CYP3A4 COMT
36 enterocolitis 10.0
37 sudden infant death syndrome 10.0
38 hepatitis c virus 10.0
39 major affective disorder 8 10.0
40 major affective disorder 9 10.0
41 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
42 fetal alcohol syndrome 10.0
43 alcohol-related birth defect 10.0
44 zika fever 10.0
45 microcephaly 10.0
46 oligohydramnios 10.0
47 ventricular septal defect 10.0
48 heart septal defect 10.0
49 hepatitis c 10.0
50 post-traumatic stress disorder 10.0

Graphical network of the top 20 diseases related to Neonatal Abstinence Syndrome:



Diseases related to Neonatal Abstinence Syndrome

Symptoms & Phenotypes for Neonatal Abstinence Syndrome

Drugs & Therapeutics for Neonatal Abstinence Syndrome

Drugs for Neonatal Abstinence Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 52)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methadone Approved Phase 4 76-99-3 4095
2
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
3
Phenylpropanolamine Approved, Vet_approved, Withdrawn Phase 4 14838-15-4 26934
4
Opium Approved, Illicit Phase 4 8008-60-4
5
Clonazepam Approved, Illicit Phase 4 1622-61-3 2802
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Clonidine Approved Phase 4 4205-90-7 2803
8 Opiate Alkaloids Phase 4
9 Respiratory System Agents Phase 4
10 Chlorpheniramine, phenylpropanolamine drug combination Phase 4
11 Antitussive Agents Phase 4
12 Opium Poppy Phase 4
13 Adrenergic alpha-Agonists Phase 4
14 Adrenergic Agents Phase 4
15 Adrenergic Agonists Phase 4
16 Antihypertensive Agents Phase 4
17 Sympatholytics Phase 4
18 Pharmaceutical Solutions Phase 4
19
Cocaine Approved, Illicit Phase 2, Phase 3 50-36-2 5760 446220
20
Phenobarbital Approved, Investigational Phase 3 50-06-6 4763
21
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
22
Chlorpromazine Approved, Investigational, Vet_approved Phase 3 50-53-3 2726
23
Chamomile Approved, Experimental, Investigational Phase 3
24 Hypnotics and Sedatives Phase 3
25 Excitatory Amino Acid Antagonists Phase 3
26 GABA Modulators Phase 3
27 Anticonvulsants Phase 3
28 Dopamine Agents Phase 3
29 Dopamine Antagonists Phase 3
30 English Lavender Phase 3
31
tannic acid Approved Phase 2 1401-55-4
32
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
33
Ondansetron Approved Phase 2 99614-02-5 4595
34
Heroin Phase 2 5462328
35 Neurotransmitter Agents Phase 2
36 Psychotropic Drugs Phase 2
37 Gastrointestinal Agents Phase 2
38 Antiemetics Phase 2
39 Antipsychotic Agents Phase 2
40 Anti-Anxiety Agents Phase 2
41 Dermatologic Agents Phase 2
42
Serotonin Investigational, Nutraceutical Phase 2 50-67-9 5202
43
Ethanol Approved 64-17-5 702
44
Hydrocortisone Approved, Vet_approved 50-23-7 5754
45
Hydrocortisone acetate Approved, Vet_approved 50-03-3
46
Naltrexone Approved, Investigational, Vet_approved 16590-41-3 5360515
47
Imidacloprid Vet_approved 105827-78-9 86418
48 Analgesics, Non-Narcotic
49 Hydrocortisone 17-butyrate 21-propionate
50 Hydrocortisone hemisuccinate

Interventional clinical trials:

(show top 50) (show all 64)
# Name Status NCT ID Phase Drugs
1 Morphine Versus Methadone for Opiate Exposed Infants With Neonatal Abstinence Syndrome Unknown status NCT02851303 Phase 4 Morphine;Methadone
2 Pharmacological Treatment of Neonatal Abstinence Syndrome: Opiate Versus Non-Opiate Completed NCT01734551 Phase 4 Morphine;Clonidine
3 Treatment of Neonatal Abstinence Syndrome: Evaluation of Efficacy of Phenobarbital in Combination With Either Methadone or Diluted Deodorized Tincture of Opium as Stabilizing and Tapering Regiments Completed NCT01723722 Phase 4 Methadone;Diluted Deodorized Tincture of Opium
4 Evaluation of Efficacy of Methadone Versus Morphine for Treatment of Neonatal Abstinence Syndrome (NAS). Completed NCT01804075 Phase 4 Methadone;Morphine
5 Optimal Morphine Dosing Schedule for Neonatal Abstinence Syndrome Recruiting NCT04298853 Phase 4 Morphine PRN;Morphine scheduled
6 Treatment of Neonatal Abstinence Syndrome With Clonidine Versus Morphine as Primary Therapy Recruiting NCT03092011 Phase 4 Clonidine;Morphine Sulfate
7 Clonidine as Adjunct to Morphine in the Management of Term and Near Term Infants With Neonatal Abstinence Syndrome Suspended NCT03762317 Phase 4 Clonidine;Placebo
8 Long Acting Subcutaneous Compared to Short Acting Sublingual Buprenorphine Administration in Pregnant and Lactating Women Withdrawn NCT04212065 Phase 4 buprenorphine
9 A Randomized, Active-Control, Double-Blind, Double-Dummy Clinical Trial Comparing Sublingual Buprenorphine And Morphine Solution For The Treatment Of Neonatal Opioid Abstinence Syndrome Completed NCT01452789 Phase 3 sublingual buprenorphine;oral morphine
10 Recovery Housing For Drug Dependent Pregnant Women Completed NCT00497302 Phase 2, Phase 3
11 Tobacco Use in Opioid Agonist Treated Pregnant Women Completed NCT00497068 Phase 2, Phase 3
12 Pharmacological Treatment of Narcotic Neonatal Withdrawal Completed NCT02810782 Phase 3 Phenobarbital;Chlorpromazine;Morphine
13 Fetal and Infant Effects of Maternal Buprenorphine Treatment Completed NCT01561079 Phase 2, Phase 3 Buprenorphine
14 Improving Outcomes in Neonatal Abstinence Syndrome Completed NCT01958476 Phase 3 Neonatal Morphine Solution;Methadone;Phenobarbital
15 The Effect of Aromatherapy on Neonatal Abstinence Syndrome and Salivary Cortisol Levels Completed NCT03097484 Phase 3 lavender and chamomile essential oils
16 Can Maternal Acupuncture for Chemically Dependent Pregnant Women Reduce the Severity of Neonatal Abstinence Syndrome? - A Randomized Controlled Trial Completed NCT00225316 Phase 3
17 Non-Opiate Treatment After Prenatal Opiate Exposure to Prevent Postnatal Injury to the Young Brain Recruiting NCT03396588 Phase 3 Clonidine;Morphine
18 Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations Recruiting NCT03918850 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
19 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): a Pragmatic Randomized Trial Comparing Extended-release and Daily Buprenorphine Formulations: Conceptual Model Assessments (CMA) Sub-study Recruiting NCT03911466 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
20 NIDA CTN Protocol 0080: Medication Treatment for Opioid Use Disorder in Expectant Mothers (MOMs): Infant Neurodevelopmental Outcomes (INO) Sub-study Not yet recruiting NCT03911739 Phase 3 Buprenorphine Injection;Buprenorphine Sublingual Product
21 Efficacy of Clonidine in Reducing Iatrogenic-induced Opioid Dependence in Infants: Terminated NCT01360450 Phase 2, Phase 3 Clonidine HCL;saline
22 Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study Unknown status NCT02249026 Phase 1, Phase 2 BZDs + opiate exposure treated with BPN;Opiates exposure treated with BPN
23 Modeled Dose Exposure of Sublingual Buprenorphine in the Neonatal Opioid Abstinence Syndrome Completed NCT03608696 Phase 1, Phase 2 Buprenorphine
24 Efficacy of Clonidine in the Treatment of Neonatal Abstinence Syndrome: A Prospective, Double Blind, Randomized Controlled Trial Completed NCT00510016 Phase 2 Clonidine HCL
25 A Randomized Comparison of Sublingual Buprenorphine to Morphine Sulfate in the Treatment of Neonatal Abstinence Syndrome (NAS) Completed NCT01708707 Phase 2 Buprenorphine;Morphine Sulfate
26 Randomized Clinical Trial of High vs. Standard-Calorie Formula for Methadone-Exposed Infants Completed NCT02178189 Phase 2
27 Prevention of Neonatal Abstinence Syndrome Completed NCT01801475 Phase 1, Phase 2 Ondansetron
28 Maternal Buprenorphine-naloxone Treatment During the Perinatal Period: Fetal and Infant Effects Recruiting NCT03291847 Phase 2 Buprenorphine Naloxone;Methadone
29 AIM 2- Prevention of Neonatal Abstinence Syndrome Active, not recruiting NCT01965704 Phase 2 Ondansetron;Placebo
30 Clonidine Versus Phenobarbital as Adjunctive Therapy for Neonatal Abstinence Syndrome Suspended NCT03670160 Phase 2 Phenobarbital;Clonidine
31 Methadone Demonstration Project With Neonatal Intensive Care Unit Infants Diagnosed With Neonatal Abstinence Syndrome Terminated NCT03134703 Phase 2 Methadone;Morphine
32 A Randomized, Open Label Clinical Trial of Buprenorphine in the Treatment of Neonatal Abstinence Syndrome in Infants With In Utero Exposure to Benzodiazepines or Are Breastfeeding Completed NCT01671410 Phase 1 oral morphine;sublingual buprenorphine
33 Buprenorphine for the Treatment of Neonatal Abstinence Syndrome Completed NCT00521248 Phase 1 buprenorphine;Oral morphine solution
34 Assessment of Actigraphy in the Management of Neonatal Opioid Abstinence Syndrome Unknown status NCT03977545
35 Relationship Between Buprenorphine Dose Adjustments and Gestational Age in the Treatment of Opioid-Maintained Pregnant Women Completed NCT03028883
36 Role of Low Lactose Infant Formula In The Management of Neonatal Abstinence Syndrome Completed NCT03549936
37 Physiology and Therapeutic Management of Neonatal Abstinence Syndrome Completed NCT02768844
38 Vagal Tone and Neonatal Abstinence Syndrome Completed NCT00496951
39 Efficacy of Auricular Acupuncture on Neonatal Abstinence Syndrome: A Randomized Controlled Trial Completed NCT02872077
40 Interest of Concentrations in Meconium of Drugs Used for Treatment of Pregnant Opioid-dependent Woman as a Prognostic Factor of Time, Severity and Duration of Neonatal Abstinence Syndrome Completed NCT03334981
41 Donor Human Milk for Infants With Neonatal Abstinence Syndrome Completed NCT02182973
42 Retrospective Analysis of the Utility Formal Psychosocial Support in Enhancing the Outcome of Pregnancies in Opiate-addicted Pregnant Women in Agonist Maintenance Programs Completed NCT01889121
43 Acupuncture Use in Infants Treated for Neonatal Abstinence Syndrome: a Pilot Study Completed NCT02062151
44 The Utility and Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome in Neonates Completed NCT01754324 Methadone
45 Feasibility of Auricular Acupressure as an Adjunct Treatment for Neonatal Abstinence Syndrome (NAS) Completed NCT03973801
46 The Use of Weighted Blankets in the Care of Infants With Neonatal Abstinence Syndrome (NAS) Completed NCT03113656
47 Mother vs. Child? Healthcare Worker Perceptions of Conflict Between Maternal Autonomy and Child Health When Providing Care for Pregnant Women Engaging in Problematic Substance Use Completed NCT02797990
48 Project RESPECT-Plus: Recovery, Empowerment, Social Services, Prenatal Care, Education and Community Treatment-Plus Completed NCT02334111
49 The PATH Home Trial: A Comparative Effectiveness Study of Peripartum Opioid Use Disorder in Rural Kentucky Recruiting NCT03725332
50 A Comparison of Mismatch Negativity Waveform Differences in Opioid-exposed and Non-exposed Neonates. Recruiting NCT03567603

Search NIH Clinical Center for Neonatal Abstinence Syndrome

Cochrane evidence based reviews: neonatal abstinence syndrome

Genetic Tests for Neonatal Abstinence Syndrome

Anatomical Context for Neonatal Abstinence Syndrome

MalaCards organs/tissues related to Neonatal Abstinence Syndrome:

40
Fetal Brain, Placenta, Heart, Liver, Tongue, Brain, Skin

Publications for Neonatal Abstinence Syndrome

Articles related to Neonatal Abstinence Syndrome:

(show top 50) (show all 1016)
# Title Authors PMID Year
1
Prenatal Opioid Analgesics and the Risk of Adverse Birth Outcomes. 61
33625160 2021
2
Parent Perspectives on the Eat, Sleep, Console Approach for the Care of Opioid-Exposed Infants. 61
33658244 2021
3
Understanding barriers to timely identification of infants at risk of neonatal opiate withdrawal syndrome. 61
31195865 2021
4
A review of the existing literature on buprenorphine pharmacogenomics. 61
33154520 2021
5
Baby STRENGTH: Eat, Sleep, Console for Infants With Neonatal Abstinence Syndrome. 61
33538494 2021
6
Neonatal abstinence syndrome and intra-uterine growth restriction secondary to maternal antimigraine drug abuse. 61
33037763 2021
7
Neonatal Abstinence Syndrome and Preterm Infants: A Look at Current Practice. 61
33756498 2021
8
Newborns With Neonatal Abstinence Syndrome Are Concentrated in Poorer-Quality Hospitals. 61
33737332 2021
9
Using buprenorphine to treat neonatal abstinence syndrome: a quality improvement study. 61
33758394 2021
10
Diagnoses during the first three years of life for children with prenatal opioid exposure and neonatal abstinence syndrome using a large maternal infant data hub. 61
33743318 2021
11
Lactose-free infant formula does not change outcomes of neonatal abstinence syndrome (NAS): a randomized clinical trial. 61
32868858 2021
12
Body composition during the first 4 months in infants affected by neonatal abstinence syndrome: a pilot study. 61
33650484 2021
13
Reduction of need for treatment and length of hospital stay following institution of a neonatal abstinence syndrome rooming-in program in Ontario, Canada. 61
33812341 2021
14
Neonatal abstinence syndrome: a systematic review of current databases and registries. 61
31092074 2021
15
Paralytic ileus in the neonate as a rare complication of maternal methadone treatment-a case report. 61
33732483 2021
16
Brotizolam During Pregnancy and Lactation: Brotizolam Levels in Maternal Serum, Cord Blood, Breast Milk, and Neonatal Serum. 61
33666494 2021
17
Torticollis in infants with neonatal abstinence syndrome. 61
31907397 2021
18
Study design and rationale for a randomized controlled trial to assess effectiveness of stochastic vibrotactile mattress stimulation versus standard non-oscillating crib mattress for treating hospitalized opioid-exposed newborns. 61
33748529 2021
19
Conceptualizing stigma in contexts of pregnancy and opioid misuse: A qualitative study with women and healthcare providers in Ohio. 61
33775446 2021
20
The North American Opioid Epidemic. 61
33337587 2021
21
Escaping the Finnegan - Is it time? 61
33663940 2021
22
Recovering Together: Mothers' Experiences Providing Skin-to-Skin Care for Their Infants With NAS. 61
33350710 2021
23
Retrospective Analysis of Oxcarbazepine in Pregnant Women With Substance Use Disorders: Focus on Safety. 61
31232158 2021
24
Pharmacometric Evaluation of Umbilical Cord Blood Concentration-Based Early Initiation of Treatment in Methadone-Exposed Preterm Neonates. 61
33668712 2021
25
Untangling the roots of the West Virginia opioid crisis: relationships in adolescent pregnancy, drug misuse, and future outcomes. 61
33567090 2021
26
Development and Validation of a Model to Predict Neonatal Abstinence Syndrome. 61
33080277 2021
27
Longitudinal Health Care Utilization of Medicaid-Insured Children with a History of Neonatal Abstinence Syndrome. 61
33545189 2021
28
The Complexities Associated with Caring for Hospitalised Infants with Neonatal Abstinence Syndrome: The Perspectives of Nurses and Midwives. 61
33671297 2021
29
Cost of neonatal abstinence syndrome: an economic analysis of English national data held in the National Neonatal Research Database. 61
33627328 2021
30
The Challenges to Promoting Attachment for Hospitalised Infants with NAS. 61
33671576 2021
31
Nurse Perceptions of Babywearing for Neonates With Neonatal Abstinence Syndrome in the Neonatal Intensive Care Unit. 61
33055521 2021
32
Developmental Outcomes of Children Born with Neonatal Abstinence Syndrome (NAS): A Scoping Review. 61
32495712 2021
33
Definitions of neonatal abstinence syndrome in clinical studies of mothers and infants: an expert literature review. 61
33514878 2021
34
The interaction of neonatal abstinence syndrome and opioid use disorder treatment availability for women insured by medicaid. 61
33025600 2021
35
Increase in Incidence of Neonatal Abstinence Syndrome Among In-Hospital Birth in the United States. 61
32658277 2021
36
Increase in Incidence of Neonatal Abstinence Syndrome Among In-Hospital Birth in the United States-Reply. 61
32658281 2021
37
Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017. 61
33433576 2021
38
Does the addition of clonidine to opioid therapy improve outcomes in infants with Neonatal Abstinence Syndrome? 61
33493373 2021
39
Association of Maternal Buprenorphine or Methadone Dose with Fetal Growth Indices and Neonatal Abstinence Syndrome. 61
31421639 2021
40
Predictive value of indicators for identifying child maltreatment and intimate partner violence in coded electronic health records: a systematic review and meta-analysis. 61
32788201 2021
41
Cleft Lip and Palate in Newborns Diagnosed With Neonatal Abstinence Syndrome. 61
32689883 2021
42
Prevalence of birth defects among infants with neonatal abstinence syndrome in Illinois, 2015-2016. 61
32896979 2021
43
Evaluating Definitions for Neonatal Abstinence Syndrome. 61
33268396 2021
44
Assessing the relationship between neonatal abstinence syndrome and birth defects in Delaware. 61
32996723 2021
45
Assessment of Neonatal Abstinence Syndrome Surveillance - Pennsylvania, 2019. 61
33444296 2021
46
Asymmetric neonatal spasms as an early sign of brain malformation potentially caused by regular light alcohol consumption during the first 22 weeks of pregnancy, a clinical case report. 61
33759420 2021
47
Ontogenetic Oxycodone Exposure Affects Early Life Communicative Behaviors, Sensorimotor Reflexes, and Weight Trajectory in Mice. 61
33692675 2021
48
Identification of Prenatal Opioid Exposure Within Health Administrative Databases. 61
33376211 2021
49
Neonatalt abstinenssyndrom blant nyfødte barn av mødre i legemiddelassistert rehabilitering. 61
33433103 2021
50
Drug Positivity Findings from a Universal Umbilical Cord Tissue Drug Analysis Program in Appalachia. 61
33324976 2021

Variations for Neonatal Abstinence Syndrome

Expression for Neonatal Abstinence Syndrome

Search GEO for disease gene expression data for Neonatal Abstinence Syndrome.

Pathways for Neonatal Abstinence Syndrome

Pathways related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.36 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
2
Show member pathways
13.01 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
3
Show member pathways
12.64 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4
Show member pathways
11.79 UGT2B7 CYP3A4 CYP2D6 CYP2B6
5
Show member pathways
11.61 CYP3A4 CYP2D6 CYP2B6
6
Show member pathways
11.5 UGT2B7 CYP3A7 CYP3A4 COMT
7
Show member pathways
11.4 CYP3A7 CYP3A4 COMT
8
Show member pathways
11.4 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
9
Show member pathways
11.32 UGT2B7 CYP3A4 CYP2D6 CYP2B6
10
Show member pathways
11.2 UGT2B7 CYP3A4 CYP2D6
11
Show member pathways
11.16 UGT2B7 CYP3A4 COMT
12 11.14 CYP3A4 CYP2B6
13
Show member pathways
11.12 CYP3A4 CYP2D6
14 11.09 CYP3A4 CYP2B6
15
Show member pathways
11.05 UGT2B7 CYP3A4 CYP2D6 CYP2B6
16
Show member pathways
10.91 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6 COMT
17 10.88 UGT2B7 CYP3A4
18
Show member pathways
10.77 CYP3A4 CYP2D6
19 10.76 UGT2B7 CYP2D6 CYP2B6
20 10.73 UGT2B7 CYP2D6
21
Show member pathways
10.54 UGT2B7 CYP3A4 CYP2D6
22 10.5 UGT2B7 CYP2D6

GO Terms for Neonatal Abstinence Syndrome

Cellular components related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 endoplasmic reticulum GO:0005783 9.91 UGT2B7 OPRM1 CYP3A7 CYP3A4 CYP2D6 CYP2B6
2 endoplasmic reticulum membrane GO:0005789 9.85 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3 dendrite GO:0030425 9.72 PNOC PDYN OPRM1 OPRK1 COMT
4 neuron projection GO:0043005 9.71 OPRM1 OPRL1 OPRK1 OPRD1
5 integral component of presynaptic membrane GO:0099056 9.54 OPRM1 OPRK1 OPRD1
6 intracellular membrane-bounded organelle GO:0043231 9.5 UGT2B7 PPIG CYP3A7 CYP3A4 CYP2D6 CYP2B6
7 integral component of synaptic vesicle membrane GO:0030285 9.49 OPRK1 OPRD1
8 dendrite membrane GO:0032590 9.48 OPRM1 OPRD1
9 organelle membrane GO:0031090 9.46 CYP3A7 CYP3A4 CYP2D6 CYP2B6
10 spine apparatus GO:0097444 9.26 OPRM1 OPRD1
11 axon terminus GO:0043679 8.92 PNOC PDYN OPRK1 OPRD1

Biological processes related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.1 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
2 lipid metabolic process GO:0006629 9.96 UGT2B7 CYP3A7 CYP3A4 CYP2D6
3 xenobiotic metabolic process GO:0006805 9.8 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4 steroid metabolic process GO:0008202 9.8 UGT2B7 CYP3A7 CYP3A4 CYP2D6 CYP2B6
5 phospholipase C-activating G protein-coupled receptor signaling pathway GO:0007200 9.76 OPRM1 OPRK1 OPRD1
6 sensory perception of pain GO:0019233 9.75 OPRM1 OPRL1 OPRK1
7 retinol metabolic process GO:0042572 9.74 CYP3A7 CYP3A4 CYP2D6
8 adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway GO:0007193 9.73 OPRM1 OPRL1 OPRK1 OPRD1
9 neuropeptide signaling pathway GO:0007218 9.73 PNOC PDYN OPRM1 OPRL1 OPRK1 OPRD1
10 drug metabolic process GO:0017144 9.7 CYP3A4 CYP2D6 CYP2B6
11 exogenous drug catabolic process GO:0042738 9.69 CYP3A4 CYP2D6 CYP2B6
12 eating behavior GO:0042755 9.67 OPRM1 OPRL1 OPRK1 OPRD1
13 response to radiation GO:0009314 9.66 OPRM1 OPRK1
14 response to morphine GO:0043278 9.65 OPRM1 OPRK1
15 retinoic acid metabolic process GO:0042573 9.65 CYP3A7 CYP3A4
16 long-chain fatty acid biosynthetic process GO:0042759 9.65 CYP3A4 CYP2D6
17 estrous cycle GO:0044849 9.65 OPRM1 OPRL1 OPRK1
18 organic acid metabolic process GO:0006082 9.64 CYP2D6 CYP2B6
19 negative regulation of cAMP-mediated signaling GO:0043951 9.64 OPRM1 OPRL1
20 androgen metabolic process GO:0008209 9.63 UGT2B7 CYP3A4
21 behavior GO:0007610 9.63 OPRL1 OPRK1
22 oxidative demethylation GO:0070989 9.63 CYP3A7 CYP3A4 CYP2D6
23 heterocycle metabolic process GO:0046483 9.62 CYP3A4 CYP2D6
24 opioid receptor signaling pathway GO:0038003 9.62 OPRM1 OPRL1 OPRK1 OPRD1
25 lipid hydroxylation GO:0002933 9.61 CYP3A7 CYP3A4
26 negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway GO:0106072 9.61 OPRM1 OPRL1
27 drug catabolic process GO:0042737 9.6 CYP3A4 CYP2D6
28 monoterpenoid metabolic process GO:0016098 9.59 CYP3A4 CYP2D6
29 conditioned place preference GO:1990708 9.56 OPRL1 OPRK1
30 alkaloid catabolic process GO:0009822 9.55 CYP3A4 CYP2D6
31 regulation of sensory perception of pain GO:0051930 9.55 OPRM1 OPRL1 OPRK1 OPRD1 COMT
32 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.54 OPRM1 OPRK1
33 estrogen metabolic process GO:0008210 9.35 UGT2B7 CYP3A7 CYP3A4 CYP2D6 COMT
34 sensory perception GO:0007600 9.02 PNOC PDYN OPRM1 OPRL1 OPRK1

Molecular functions related to Neonatal Abstinence Syndrome according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.88 CYP3A7 CYP3A4 CYP2D6 CYP2B6
2 heme binding GO:0020037 9.78 CYP3A7 CYP3A4 CYP2D6 CYP2B6
3 iron ion binding GO:0005506 9.76 CYP3A7 CYP3A4 CYP2D6 CYP2B6
4 monooxygenase activity GO:0004497 9.73 CYP3A7 CYP3A4 CYP2D6 CYP2B6
5 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.71 CYP3A7 CYP3A4 CYP2D6 CYP2B6
6 peptide binding GO:0042277 9.67 OPRM1 OPRL1 OPRK1 OPRD1
7 oxygen binding GO:0019825 9.58 CYP3A7 CYP3A4
8 aromatase activity GO:0070330 9.57 CYP3A7 CYP3A4
9 retinoic acid 4-hydroxylase activity GO:0008401 9.56 CYP3A7 CYP3A4
10 steroid hydroxylase activity GO:0008395 9.56 CYP3A7 CYP3A4 CYP2D6 CYP2B6
11 estrogen 16-alpha-hydroxylase activity GO:0101020 9.55 CYP3A7 CYP3A4
12 receptor serine/threonine kinase binding GO:0033612 9.54 OPRK1 OPRD1
13 testosterone 6-beta-hydroxylase activity GO:0050649 9.52 CYP3A7 CYP3A4
14 opioid receptor binding GO:0031628 9.51 PNOC PDYN
15 estrogen 2-hydroxylase activity GO:0101021 9.5 CYP3A7 CYP3A4 CYP2B6
16 opioid peptide activity GO:0001515 9.49 PNOC PDYN
17 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.46 CYP3A7 CYP3A4 CYP2D6 CYP2B6
18 neuropeptide binding GO:0042923 9.26 OPRM1 OPRL1 OPRK1 OPRD1
19 opioid receptor activity GO:0004985 8.92 OPRM1 OPRL1 OPRK1 OPRD1

Sources for Neonatal Abstinence Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....